Psoriasis induced by Interferon alfa-2a and ribavirin in a patient followed for hepatitis C

Psoriasis induced by Interferon alfa-2a and ribavirin in a patient followed for hepatitis C

In patients suffering from chronic hepatitis C, Interferon (INF) associated with ribavirin therapy can induce various side effects involving the skin. Our case describes the clinical course of a patient with chronic hepatitis C treated with pegylated α2 INF plus ribavirin. After 6 weeks of therapy h...

Full description

Bibliographic Details
Main Authors:	N. Amraoui, S. Gallouj, N. Oubelkacem, W. Bono, F. Mernissi
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2015-07-01
Series:	Journal of Dermatology and Dermatologic Surgery
Subjects:	Hepatitis C Pegylated Interferon alfa-2a Ribavirin Psoriasis
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352241015000195

Similar Items

Pityriasis Rosea Associated with Pegylated Interferon Alfa and Ribavirin Treatment in a Patient with Chronic Hepatitis C
by: Rahmet Güner, et al.
Published: (2013-06-01)

Autoimmune thyroid diseases in patients with chronic hepatitis C treated by pegylated interferon-alpha and ribavirin: A prospective study
by: Ružić Maja, et al.
Published: (2017-01-01)

Response factors to pegylated interferon-alfa/ribavirin treatment in chronic hepatitis C patients genotype 1b
by: Jovanović-Ćupić Snežana, et al.
Published: (2014-01-01)

Efficacy, tolerability and safety in the treatment of chronic hepatitis C with combination of PEG-Interferon – Ribavirin in daily practice
by: Ezequiel Ridruejo, MD., et al.
Published: (2010-01-01)

Characteristics of hepatitis C treatment with pegylated interferons and ribavirin
by: Ricardo Jiménez-Méndez, et al.
Published: (2010-01-01)

Efficacy of combined antiviral therapy with pegylated interferon α-2a and ribavirin for chronic hepatitis C infection in intravenous drug users
by: Ružić Maja, et al.
Published: (2010-01-01)

EFFICACY AND SAFETY OF THE COMBINATION OF RIBAVIRIN AND PEGYLATED INTERFERON ALFA-2A IN PATIENTS WITH CHRONIC HEPATITIS C: THE RESULTS OF TWO MULTICENTER, PROSPECTIVE, OPEN, NON-COMPARATIVE CLINICAL TRIALS
by: K. V. Zhdanov, et al.
Published: (2018-01-01)

Treatment of human papillomavirus with peg-interferon alfa-2b and ribavirin
by: M.H.P. Pavan, et al.

Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan
by: Jung-An Lin, et al.
Published: (2014-10-01)

Pegylated Interferon (Alone or With Ribavirin) for Chronic Hepatitis C in Haemodialysis Population
by: Mario Espinosa, et al.
Published: (2015-05-01)

Combined pegylated interferon and ribavirin for the management of chronic hepatitis C in a prison setting
by: Sergio Sabbatani, et al.

Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin
by: Janine Hartl, et al.
Published: (2012-07-01)

Importance of adherence for efficacy of hepatitis C combined therapy
by: Nožić Darko, et al.
Published: (2013-01-01)

The interleukin 28B gene polymorphism, rs8099917, in patients with chronic hepatitis C and response to the treatment with pegylated interferon and ribavirin
by: Hamid Kalantari, et al.
Published: (2019-01-01)

Autoantibodies profile in patients with chronic hepatitis C and the influence of Interferon-alfa plus Ribavirin
by: Janaina LeitÃo Vilar
Published: (2006)

Using pegylated interferon alfa-2b and ribavirin to treat chronic hepatitis patients infected with hepatitis c virus genotype 1: are nonresponders and relapsers different populations?
by: Giovanni Faria Silva, et al.

The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients
by: Nishikawa Hiroki, et al.
Published: (2012-03-01)

Side Effects of Therapy for Chronic Hepatitis C: High Incidence of Dermal and Mucosal Adverse Events
by: Hüseyin Şener BARUT, et al.
Published: (2010-03-01)

Histological response study of chronic viral hepatitis C patients treated with interferon alone or combined with ribavirin
by: Kleber Prado, et al.

Five-year follow-up of patients with chronic C hepatitis and sustained virological response Seguimiento a 5 años de pacientes con hepatitis crónica C y respuesta viral sostenida
by: I. Puig-del-Castillo, et al.
Published: (2011-02-01)

Survival of hepatitis C-infected haemophilia patients is predicted by presence of cirrhosis but not by anti-viral treatment
by: Yaakov Maor, et al.
Published: (2014-11-01)

Toll-like receptors 7 and 8 mRNA in monocytes of Egyptian children with chronic hepatitis C infection genotype 4 as predictor to “response” interferon and ribavirin treatment
by: Mohammed A. Khedr, et al.
Published: (2016-03-01)

Clinical efficacy of ribavirin combined with different doses of interferon α-2b in patients with chronic hepatitis C genotypes 2 and 3
by: ZHAO Xiaoling
Published: (2013-10-01)

Antiviral/immunomodulatory combination therapy: Pegylated interferon alpha 2a and ribavirin in patients with chronic hepatitis C virus infection
by: Delić Dragan, et al.
Published: (2012-01-01)

Tratamento de pacientes com hepatite crônica pelo vírus C com interferon-alfa e ribavirina: a experiência da Secretaria de Saúde do Rio Grande do Sul Interferon-alpha and ribavirin therapy on chronic hepatitis C virus infection: the experience of Rio Grande do Sul State Health Department, Brazil
by: Alexandro Vaesken Alves, et al.
Published: (2003-12-01)

Daily interferon induction regimen using different manufactured interferons (alpha-2a or alpha-2b) in combination with ribavirin for treatment of chronic hepatitis C: a prospective randomized study Esquema de indução diário com interferon alfa 2-a ou alfa 2-b em combinação com ribavirina para tratamento da hepatite crônica C: estudo prospectivo randomizado
by: Eduardo Lorens Braga, et al.
Published: (2006-12-01)

Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy
by: E. Parise, et al.

Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort
by: Ta-Wei Liu, et al.
Published: (2018-01-01)

Early virologic response to сеpeginterferon alfa-2b in combination with ribavirin in treatment of patients with chronic hepatitis C
by: O. O. Znoyko, et al.
Published: (2014-09-01)

Interferon-ribavirin therapy for chronic hepatitis C: Efficacy in Saudi patients
by: Sandokji Abdulkareem, et al.
Published: (2003-01-01)

Therapy with interferon-alpha plus ribavirin for membranoproliferative glomerulonephritis induced by hepatitis C virus
by: Edmundo P.A. Lopes, et al.

Therapy with interferon-a plus ribavirin for membranoproliferative glomerulonephritis induced by hepatitis C virus
by: Lopes Edmundo P.A., et al.
Published: (2003-01-01)

A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C
by: Byung Chul You, et al.
Published: (2012-09-01)

Effect of Pegylated Interferon on Non-Responders and Relapsers with Interferon
by: Hisham O. Akbar, et al.
Published: (2002-04-01)

Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers
by: Marisa Boff Costa, et al.
Published: (2018-01-01)

An open, non-controlled clinical study to assess the efficacy and safety of the recombinant human alpha 2b pegylated interferon PEG-Heberon® plus ribavirin for the treatment of chronic hepatitis C virus infection in Cuban patients
by: Marlen I Castellanos-Fernández, et al.

Interleukin-28B (rs12979860) gene variation and treatment outcome after peginterferon plus ribavirin therapy in patients with genotype 1 of hepatitis C virus
by: Hamid Kalantari, et al.
Published: (2014-01-01)

New approaches and therapeutic modalities for the treatment of patients with chronic hepatitis C
by: Markus Cornberg, et al.
Published: (2005-07-01)

Telaprevir: New possibilities for antiviral treatment in patients with chronic hepatitis C
by: I G Nikitin, et al.
Published: (2012-11-01)

Extended treatment with interferon and ribavirin in a hemodialysis patient with chronic hepatitis C
by: Aline Gonzalez Vigani, et al.

Cannot write session to /tmp/vufind_sessions/sess_ft1v1d8a2u6kf8p8c24e6vikg1